DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence-based Clinical Trial Solutions for Patient Matching - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering ...
Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin. Intergroup randomized phase III study of ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for ...
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C Merck ...
A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. Background: To serve as a bridge between preclinical and early clinical testing, pre-surgical studies are being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback